Rheumatology International

, Volume 32, Issue 4, pp 1049–1053 | Cite as

Development of sarcoidosis following etanercept treatment: a report of three cases

  • Inger Marie SkoieEmail author
  • Klaus Wildhagen
  • Roald Omdal
Case Report


After over 10 years of use of tumor necrosis factor-alpha (TNF-α) inhibitors, their side effects and complications are reasonably well documented. Recently, however, granulomatous reactions and cases of complete sarcoidosis have been reported, especially in patients treated with the TNF-α receptor protein, etanercept. This is intriguing because the TNF-α antibody drugs infliximab and adalimumab are reportedly used to treat sarcoidosis. We present three patients who developed sarcoidosis while on etanercept treatment, and discuss if possible differences in cytokine profiles and T regulatory cell function in patients taking different TNF-α inhibitors may explain this paradox.


Tumor necrosis factor-alpha inhibitors Sarcoidosis Cytokines T regulatory cells 


  1. 1.
    Massara A, Cavazzini L, La Corte R, Trotta F (2009) Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2009 14 Jan [Epub ahead of print]Google Scholar
  2. 2.
    Daïen CI, Monnier A, Claudepierre P et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48(8):865–866CrossRefGoogle Scholar
  3. 3.
    Josse S, Klemmer N, Moreno-Swirc S, Goëb V, Lequerré T, Vittecoq O (2009) Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient. Jt Bone Spine 76(6):718–719CrossRefGoogle Scholar
  4. 4.
    Metyas SK, Tadros RM, Arkfeld DG (2009) Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 29:437–439PubMedCrossRefGoogle Scholar
  5. 5.
    Toussirot E, Pertuiset E, Kantelip B, Wendling D (2008) Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 26:471–475PubMedGoogle Scholar
  6. 6.
    González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V (2006) Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55:817–820PubMedCrossRefGoogle Scholar
  7. 7.
    Ishiguro T, Takayanagi N, Kurashima K et al (2008) Development of sarcoidosis during etanercept therapy. Intern Med 47:1021–1025PubMedCrossRefGoogle Scholar
  8. 8.
    Farah RE, Shay MD (2007) Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 27:1446–1448PubMedCrossRefGoogle Scholar
  9. 9.
    Almodóvar R, Izquierdo M, Zarco P, Javier Quirós F, Mazzucchelli R, Steen B (2007) Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 25:99–101PubMedGoogle Scholar
  10. 10.
    Kudrin A, Chilvers ER, Ginawi A et al (2007) Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol 34:648–649PubMedGoogle Scholar
  11. 11.
    Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R (2007) Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 26:1969–1971PubMedCrossRefGoogle Scholar
  12. 12.
    O’Shea FD, Marras TK, Inman RD (2006) Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 55:978–981PubMedCrossRefGoogle Scholar
  13. 13.
    Hashkes PJ, Shajrawi I (2003) Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 21:645–646PubMedGoogle Scholar
  14. 14.
    Phillips K, Weinblatt M (2005) Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 53:618–620PubMedCrossRefGoogle Scholar
  15. 15.
    Vavricka SR, Wettstein T, Speich R, Gaspert A, Bachli EB (2003) Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. Thorax 58:278–279PubMedCrossRefGoogle Scholar
  16. 16.
    Peno-Green L, Lluberas G, Kingsley T, Brantley S (2002) Lung injury linked to etanercept therapy. Chest 122:1858–1860PubMedCrossRefGoogle Scholar
  17. 17.
    Sturfelt G, Christensson B, Bynke G, Saxne T (2007) Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 34:2313–2314PubMedGoogle Scholar
  18. 18.
    Louie GH, Chitkara P, Ward MM (2008) Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis 67:896–898PubMedCrossRefGoogle Scholar
  19. 19.
    Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168:4620–4627PubMedGoogle Scholar
  20. 20.
    Baughman RP, Drent M, Kavuru M, Sarcoidosis Investigators et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802PubMedCrossRefGoogle Scholar
  21. 21.
    Rossman MD, Newman LS, Baughman RP et al (2006) A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:201–208PubMedGoogle Scholar
  22. 22.
    Utz JP, Limper AH, Kalra S et al (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177–185PubMedCrossRefGoogle Scholar
  23. 23.
    Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128:47–1062CrossRefGoogle Scholar
  24. 24.
    Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094PubMedCrossRefGoogle Scholar
  25. 25.
    Brown SJ, Abreu MT (2005) Antibodies to tumor necrosis factor-alpha in the treatment of Crohn’s disease. Curr Opin Drug Discov Dev 8:160–168Google Scholar
  26. 26.
    Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885PubMedCrossRefGoogle Scholar
  27. 27.
    Sandborn WJ, Hanauer S, Loftus EV Jr et al (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 99:1984–1989PubMedCrossRefGoogle Scholar
  28. 28.
    Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104PubMedCrossRefGoogle Scholar
  29. 29.
    Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRefGoogle Scholar
  30. 30.
    Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159–167PubMedCrossRefGoogle Scholar
  31. 31.
    Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34:34–38PubMedCrossRefGoogle Scholar
  32. 32.
    Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357:2153–2165PubMedCrossRefGoogle Scholar
  33. 33.
    Ziegenhagen MW, Müller-Quernheim J (2003) The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 253:18–30PubMedCrossRefGoogle Scholar
  34. 34.
    Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE (2006) TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells. Blood 108:253–261PubMedCrossRefGoogle Scholar
  35. 35.
    Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200:277–285PubMedCrossRefGoogle Scholar
  36. 36.
    Idali F, Wahlström J, Müller-Suur C, Eklund A, Grunewald J (2008) Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis. Clin Exp Immunol 152:127–137PubMedCrossRefGoogle Scholar
  37. 37.
    Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486–492PubMedCrossRefGoogle Scholar
  38. 38.
    Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431–1442PubMedCrossRefGoogle Scholar
  39. 39.
    Doyle MK, Berggren R, Magnus JH (2006) Interferon-induced sarcoidosis. J Clin Rheumatol 12:241–248PubMedCrossRefGoogle Scholar
  40. 40.
    Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249–2254PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Inger Marie Skoie
    • 1
    Email author
  • Klaus Wildhagen
    • 1
  • Roald Omdal
    • 1
  1. 1.Clinical Immunology Unit, Department of Internal MedicineStavanger University HospitalStavangerNorway

Personalised recommendations